INVO Fertility has recently expanded its fertility services through new therapies and telehealth, reported financial results emphasizing core operations, and experienced share price movements linked to patent issuance and stock splits.

• INVO Fertility enhanced fertility services with expanded training and improved INVOcell pricing [N5].
• The company introduced platelet-rich plasma therapy at the Wisconsin Fertility Institute to expand its fertility service offerings [N6].
• INVO Fertility expanded telehealth services to improve access to expert fertility care in multiple states [N7].
• Reported Q1 2025 financial results highlighted a strategic focus on core fertility operations [N8].
• Reported record revenue growth in Q4 2024 and full year 2024 financial results [N8].
• Implemented a 1-for-3 reverse stock split effective July 21, 2025, and announced plans for additional reverse stock splits [N3][N4].
• Shares surged following patent issuance for a modified INVOcell device [N1].
• Shares increased over 300% in early 2026 [N2].

The company has demonstrated revenue growth and strategic expansion of its fertility services, including telehealth and innovative therapies. The issuance of a patent for a modified INVOcell device may enhance its product portfolio and market position. Recent share price appreciation reflects market interest in these developments. INVO Fertility's focus on core fertility operations and service enhancements could support continued operational progress.

INVO Fertility reported a net loss and negative earnings per share as of Q1 2026, with liquidity ratios below 1 indicating potential short-term financial constraints. The company has implemented multiple reverse stock splits, which may reflect challenges in maintaining share price levels. The fertility services market is competitive and subject to regulatory risks, which could impact the company's ability to sustain growth and profitability.

INVO Fertility's moat is supported by its proprietary INVOcell device, for which it has recently received a patent for a modified version, potentially strengthening its competitive position. The company's expansion into telehealth and novel fertility therapies such as platelet-rich plasma therapy may also contribute to differentiation in the fertility services market. However, the fertility services industry is competitive and subject to regulatory and reimbursement challenges.

• Financial Performance Risk: The company reported a net loss of $5.5 million and negative earnings per share in Q1 2026, indicating ongoing profitability challenges [S2].
• Liquidity Risk: Current liabilities exceed current assets as of March 31, 2026, with a current ratio of 0.9 and a cash ratio of 0.31, suggesting potential short-term liquidity constraints [S2].
• Market and Regulatory Risk: The fertility services industry is competitive and subject to regulatory changes that could affect operations and reimbursement.
• Stock Price Volatility and Reverse Splits: Multiple reverse stock splits have been implemented, which may indicate volatility and challenges in maintaining market capitalization [N3][N4].

• INVO Fertility, Inc. is a publicly traded company on Nasdaq under the ticker IVF [S1].
• The company operates in the fertility services sector, providing fertility-related medical services and products [N5][N6][N7].
• INVO Fertility has expanded its fertility services by introducing platelet-rich plasma therapy at the Wisconsin Fertility Institute [N6].
• The company has enhanced its fertility services with expanded training programs and improved pricing for its INVOcell device [N5].
• INVO Fertility has expanded telehealth services to improve access to expert fertility care across multiple states [N7].
• The company reported Q1 2025 financial results emphasizing a strategic focus on core fertility operations [N8].
• INVO Fertility reported record revenue growth in Q4 2024 and full year 2024 financial results [N8].
• The company has implemented multiple reverse stock splits, including a 1-for-3 reverse stock split effective July 21, 2025, and announced plans for further reverse splits [N3][N4].
• INVO Fertility shares surged following the issuance of a patent for a modified INVOcell device [N1].
• The company experienced a share price increase of over 300% in early 2026 [N2].
• As of March 31, 2026, INVO Fertility reported revenue of $2,015,225 USD and a net loss of $5,539,351 USD [S2].
• Earnings per share (basic and diluted) were -$3.38 as of March 31, 2026 [S2].
• The company had cash and cash equivalents of $1,962,159 USD and current assets of $5,734,161 USD as of March 31, 2026 [S2].
• Current liabilities were $6,355,838 USD as of March 31, 2026, resulting in a current ratio of 0.9 and a cash ratio of 0.31 [S2].
• The number of shares outstanding as of June 12, 2026 was 1,786,035 [S1].
• The company is incorporated in Nevada and headquartered in Sarasota, Florida [S1].
• The executive leadership includes CEO Steven Shum, CFO Terah Krigsvold, and Chief Business Officer Andrea Goren [S1].